News

With aim to finance the transaction through a combination of cash on hand and debt, Cognizant has already secured $1bn of committed financing in support of the transaction,

GSK paid $1.5m to obtain an exclusive, worldwide license to products containing or directed to an undisclosed muscle disease target discovered by Five Prime using its proprietary library

The first of these agreements is a joint development program with St. Jude Children’s Research Hospital (Memphis, Tennessee, United States, "St. Jude") and the non-profit public-private partnership Medicines

The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer (CRPC) who have rising Prostate-Specific Antigen (PSA) levels and no detectable metastases. The trial is designed

Results from the study, presented during the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), also confirmed the safety profile of the combination

In October 2014, Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma

The GNHA assembled this summer to discuss the current VMS landscape, concluding it is riddled with inconsistent messages and misconceptions that ultimately may confuse both healthcare professionals and

ChromaDex’s NIAGEN™ is the first and only commercially available form of nicotinamide riboside (NR), a naturally occurring no-flush vitamin B3 metabolite found in milk. Published research has shown

In this analysis, survival in patients with HPP at high risk of death who were treated with asfotase alfa for up to five years was significantly improved (89%